According to filings with the U.S. Securities and Exchange Commission, Rivus Pharmaceuticals is raising up to $66,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Allen Cunningham played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Rivus Pharmaceuticals
Rivus Pharmaceuticals, Inc., is dedicated to transforming the treatment of cardio-metabolic disease by advancing a new class of oral, once daily, small molecule therapeutics called Controlled Metabolic Accelerators (CMAs). Rivus CMAs are designed to improve cellular metabolism and treat the underlying cause of highly prevalent metabolic and cardiovascular diseases including type 2 diabetes, severe hypertriglyceridemia (SHTG), non-alcoholic steatohepatitis (NASH), as well as cardiovascular diseases such as heart failure with reduced ejection fraction (HFpEF).

To learn more about Rivus Pharmaceuticals, visit http://www.rivuspharma.com/
Rivus Pharmaceuticals Linkedin Page: https://www.linkedin.com/company/rivus-pharmaceuticals/

Contact:
Allen Cunningham, Chief Executive Officer
703-456-8000
https://www.linkedin.com/in/allen-cunningham-3a31b6202/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.